Table 2.
Ranking and characteristics of the top-cited reviews on cysticercosis and neurocysticercosis.
| Overall rank | Review rank | Publication | Topic | Country of origin | N citations | Citation density | |
|---|---|---|---|---|---|---|---|
| 1st author | Last author | ||||||
| 2 | 1 | Del Brutto OH, Rajshekhar V, White AC Jr, et al Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57(2):177-183. doi:10.1212/wnl.57.2.177 | Diagnosis, clinical presentation | Peru | Peru | 537 | 28.29 |
| 3 | 2 | García HH, Gonzalez AE, Evans CA, Gilman RH; Cysticercosis Working Group in Peru. Taenia solium cysticercosis. Lancet. 2003;362(9383):547-556. doi:10.1016/S0140-6736(03)14117-7 | All aspects | Peru | USA | 456 | 26.82 |
| 6 | 3 | Garcia HH, Del Brutto OH; Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. 2005;4(10):653-661. doi:10.1016/S1474-4422(05)70194-0 | All aspects | Peru | Peru | 318 | 21.2 |
| 8 | 4 | García HH, Evans CA, Nash TE, et al Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15(4):747-756. doi:10.1128/CMR.15.4.747-756.2002 | Therapeutics | Peru | USA | 278 | 15.44 |
| 9 | 5 | Del Brutto OH, Sotelo J. Neurocysticercosis: an update. Rev Infect Dis. 1988;10(6):1075-1087. doi:10.1093/clinids/10.6.1075 | All aspects | Peru | Mexico | 263 | 8.22 |
| 10 | 6 | Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014;13(12):1202-1215. doi:10.1016/S1474-4422(14)70094-8 | All aspects | Peru | Peru | 262 | 43.67 |
| 7 | 11 | Ndimubanzi PC, Carabin H, Budke CM, et al A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 2010;4(11):e870. Published 2010 Nov 2. doi:10.1371/journal.pntd.0000870 | Central nervous system & epilepsy | USA | USA | 258 | 25.8 |
| 12 | 8 | White AC Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis. 1997;24(2):101-115. doi:10.1093/clinids/24.2.101 | Central nervous system & epilepsy | USA | USA | 256 | 11.13 |
| 19 | 9 | White AC Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu Rev Med. 2000;51:187-206. doi:10.1146/annurev.med.51.1.187 | All aspects | USA | USA | 221 | 11.05 |
| 20 | 10 | Carpio A. Neurocysticercosis: an update. Lancet Infect Dis. 2002;2(12):751-762. doi:10.1016/s1473-3099(02)00454-1 | All aspects | Ecuador | Ecuador | 207 | 11.5 |
| 23 | 11 | Carpio A, Escobar A, Hauser WA. Cysticercosis and epilepsy: a critical review. Epilepsia. 1998;39(10):1025-1040. doi:10.1111/j.1528-1157.1998.tb01287.x | Central nervous system & epilepsy | Ecuador | USA | 196 | 5.16 |
| 25 | 12 | Carabin H, Ndimubanzi PC, Budke CM, et al Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis. 2011;5(5):e1152. doi:10.1371/journal.pntd.0001152 | Clinical | USA | USA | 190 | 21.11 |
| 26 | 13 | Román G, Sotelo J, Del Brutto O, et al A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ. 2000;78(3):399-406 | Epidemiology | USA | Brazil | 188 | 9.4 |
| 30 | 14 | Sciutto E, Fragoso G, Fleury A, et al Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Microbes Infect. 2000;2(15):1875-1890. doi:10.1016/s1286-4579(00)01336-8 | All aspects | Mexico | Mexico | 162 | 8.1 |
| 32 | 15 | Del Brutto OH, Wadia NH, Dumas M, Cruz M, Tsang VC, Schantz PM. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci. 1996;142(1-2):1-6. doi:10.1016/0022-510 × (96)00130-x | Diagnosis, clinical presentation | Peru | USA | 161 | 5.75 |
| 35 | 16 | Rickard MD, Williams JF. Hydatidosis/cysticercosis: immune mechanisms and immunization against infection. Adv Parasitol. 1982;21:229-296. doi:10.1016/s0065-308 × (08)60277-8 | Imaging | Australia | USA | 160 | 5.71 |
| 36 | 17 | Nash TE, Del Brutto OH, Butman JA, et al Calcific neurocysticercosis and epileptogenesis. Neurology. 2004;62(11):1934-1938. doi:10.1212/01.wnl.0000129481.12067.06 | Central nervous system & epilepsy | USA | Peru | 160 | 4.21 |
| 38 | 18 | García HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Trop. 2003;87(1):71-78. doi:10.1016/s0001-706 × (03)00057-3 | Imaging | Peru | Peru | 147 | 8.65 |
| 40 | 19 | Del Brutto OH, Nash TE, White AC Jr, et al Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017;372:202-210. doi:10.1016/j.jns.2016.11.045 | Diagnosis, clinical presentation | Peru | Peru | 146 | 4.42 |
| 47 | 20 | Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006;145(1):43-51. doi:10.7326/0003-4819-145-1-200607040-00009 | Therapeutics | Peru | Peru | 141 | 4.7 |
| 49 | 21 | Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. 2004;63(9):1559-1564. doi:10.1212/01.wnl.0000142979.98182.ff | Epidemiology | USA | USA | 138 | 8.63 |